Myths vs facts: CYP2D6 and gut health

CYP2D6 is a liver enzyme primarily involved in metabolizing about 25% of all prescription drugs (e.g., antidepressants, beta-blockers, opioids). There is no direct, scientifically established link between CYP2D6 genetic variants and gut health. A common myth suggests that CYP2D6 influences the gut microbiome or digestion – but robust evidence is lacking. Gut health is mainly determined by diet, microbiome composition, intestinal barrier function, and immune status. CYP2D6 may become indirectly relevant when drugs processed by this enzyme affect gut function (e.g., opioid-induced constipation). Additionally, CYP2D6 participates in serotonin synthesis, which could theoretically modulate the gut-brain axis, but clinical significance remains unclear. A DNA test for CYP2D6 is not indicated for gut health assessment. The evidence is mostly mechanistic and speculative. Consumers should not rely on such myths but instead focus on proven strategies: fiber-rich diet, probiotics, and medical evaluation for persistent symptoms.